ASH 2024 | MCL updates from ASH 2024 and the key takeaways for community oncologists

So a lot is happening in mantle cell lymphoma, especially at this ASH meeting. In yesterday’s mantle cell session, I would say two of the big highlights were we got longer-term follow-up of the Triangle study. That was a study in younger patients looking at the incorporation of a BTK inhibitor, ibrutinib, into intensive therapy and then this question around whether autologous transplant consolidation is a benefit. I think the summary that is really important for the community of oncology doctors is that the benefit of autologous transplant seems to be going away. There were some subgroup analyses that suggested, perhaps in high-risk patients, those that have high Ki-67, perhaps in patients who have P53 abnormalities, there could be some benefit, although I would say those are really subgroup analyses. The overall study tells us that for the majority of patients, there may not be a benefit to autologous transplant. 

There’s a late-breaking abstract that we’re really all excited to see, looking at a similar question from a slightly different perspective that was done by the U.S. Cooperative Group study, and that abstract basically summarizes that patients who get really deep responses to induction therapy didn’t seem to benefit from autologous transplant consolidation. So I think that’s a really important take-home for our community oncology physicians is that transplant may not be as important of a tool going forward, and there may be a continued role for inclusion of BTK inhibitors into that frontline regimen. It’s going to vary depending on the backbone we use and the age and comorbidities of the patients that we’re treating.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.